Curcumin-based-fluorescent probes targeting ALDH1A3 as a promising tool for glioblastoma precision surgery and early diagnosis.
Journal
Communications biology
ISSN: 2399-3642
Titre abrégé: Commun Biol
Pays: England
ID NLM: 101719179
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
received:
27
05
2021
accepted:
09
08
2022
entrez:
1
9
2022
pubmed:
2
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Glioblastoma (GBM) is the most aggressive primary brain tumour for which both effective treatments and efficient tools for an early-stage diagnosis are lacking. Herein, we present curcumin-based fluorescent probes that are able to bind to aldehyde dehydrogenase 1A3 (ALDH1A3), an enzyme overexpressed in glioma stem cells (GSCs) and associated with stemness and invasiveness of GBM. Two compounds are selective versus ALDH1A3, without showing any appreciable interaction with other ALDH1A isoenzymes. Indeed, their fluorescent signal is detectable only in our positive controls in vitro and absent in cells that lack ALDH1A3. Remarkably, in vivo, our Probe selectively accumulate in glioblastoma cells, allowing the identification of the growing tumour mass. The significant specificity of our compounds is the necessary premise for their further development into glioblastoma cells detecting probes to be possibly used during neurosurgical operations.
Identifiants
pubmed: 36050388
doi: 10.1038/s42003-022-03834-7
pii: 10.1038/s42003-022-03834-7
pmc: PMC9437101
doi:
Substances chimiques
Fluorescent Dyes
0
Aldehyde Oxidoreductases
EC 1.2.-
Aldehyde Dehydrogenase
EC 1.2.1.3
aldehyde dehydrogenase (NAD(P)+)
EC 1.2.1.5
Curcumin
IT942ZTH98
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
895Informations de copyright
© 2022. The Author(s).
Références
Louis, D. N. et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-Oncology. 23, 1231–1251 (2021).
pubmed: 34185076
pmcid: 8328013
doi: 10.1093/neuonc/noab106
Phillips, H. S. et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9, 157–173 (2006).
pubmed: 16530701
doi: 10.1016/j.ccr.2006.02.019
Verhaak, R. G. W. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98–110 (2010).
pubmed: 20129251
pmcid: 2818769
doi: 10.1016/j.ccr.2009.12.020
Dunn, G. P. et al. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26, 756–784 (2012).
pubmed: 22508724
pmcid: 3337451
doi: 10.1101/gad.187922.112
Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med. 23, 1124–1134 (2017).
pubmed: 28985214
doi: 10.1038/nm.4409
Chen, X., Liao, R., Li, D. & Sun, J. Induced cancer stem cells generated by radiochemotherapy and their therapeutic implications. Oncotarget 8, 17301–17312 (2017).
pubmed: 28038467
doi: 10.18632/oncotarget.14230
Fedele, M., Cerchia, L., Pegoraro, S., Sgarra, R. & Manfioletti, G. Proneural-mesenchymal transition: phenotypic plasticity to acquire multitherapy resistance in glioblastoma. IJMS 20, 2746 (2019).
pmcid: 6600373
doi: 10.3390/ijms20112746
Behnan, J., Finocchiaro, G. & Hanna, G. The landscape of the mesenchymal signature in brain tumours. Brain 142, 847–866 (2019).
pubmed: 30946477
pmcid: 6485274
doi: 10.1093/brain/awz044
Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396–401 (2004).
pubmed: 15549107
doi: 10.1038/nature03128
Carro, M. S. et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 463, 318–325 (2010).
pubmed: 20032975
doi: 10.1038/nature08712
Mao, P. et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc. Natl Acad. Sci. USA 110, 8644–8649 (2013).
pubmed: 23650391
pmcid: 3666732
doi: 10.1073/pnas.1221478110
Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
pubmed: 15758009
doi: 10.1056/NEJMoa043330
Perry, J. R. et al. Short-course radiation plus temozolomide in elderly patients with glioblastoma. N. Engl. J. Med. 376, 1027–1037 (2017).
pubmed: 28296618
doi: 10.1056/NEJMoa1611977
Zhang, W. et al. ALDH1A3: a marker of mesenchymal phenotype in gliomas associated with cell invasion. PLoS ONE 10, e0142856 (2015).
pubmed: 26575197
pmcid: 4648511
doi: 10.1371/journal.pone.0142856
Ferraris, D. M., Gelardi, E. L. M., Garavaglia, S., Miggiano, R. & Rizzi, M. Targeting NAD-dependent dehydrogenases in drug discovery against infectious diseases and cancer. Biochem. Soc. Trans. 48, 693–707 (2020).
pubmed: 32311017
doi: 10.1042/BST20191261
Koppaka, V. et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharm. Rev. 64, 520–539 (2012).
pubmed: 22544865
pmcid: 3400832
doi: 10.1124/pr.111.005538
Marchitti, S. A., Brocker, C., Stagos, D. & Vasiliou, V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert Opin. Drug Metab. Toxicol. 4, 697–720 (2008).
pubmed: 18611112
pmcid: 2658643
doi: 10.1517/17425255.4.6.697
Moretti, A. et al. Crystal structure of human aldehyde dehydrogenase 1A3 complexed with NAD+ and retinoic acid. Sci. Rep. 6, 35710 (2016).
pubmed: 27759097
pmcid: 5069622
doi: 10.1038/srep35710
Duan, J.-J., Cai, J., Guo, Y.-F., Bian, X.-W. & Yu, S.-C. ALDH1A3, a metabolic target for cancer diagnosis and therapy. Int. J. Cancer 139, 965–975 (2016).
pubmed: 26991532
doi: 10.1002/ijc.30091
Tomita, H., Tanaka, K., Tanaka, T. & Hara, A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget 7, 11018–11032 (2016).
pubmed: 26783961
pmcid: 4905455
doi: 10.18632/oncotarget.6920
Nwani, N. et al. A novel ALDH1A1 inhibitor targets cells with stem cell characteristics in ovarian cancer. Cancers 11, 502 (2019).
pmcid: 6521036
doi: 10.3390/cancers11040502
Kharkar, P. S. Cancer stem cell (CSC) inhibitors in oncology—a promise for a better therapeutic outcome: state of the art and future perspectives. J. Med. Chem. 63, 15279–15307 (2020).
pubmed: 33325699
doi: 10.1021/acs.jmedchem.0c01336
Gelardi, E. L. M. et al. A selective competitive inhibitor of aldehyde dehydrogenase 1A3 hinders cancer cell growth, invasiveness and stemness in vitro. Cancers 13, 356 (2021).
pubmed: 33478031
pmcid: 7835878
doi: 10.3390/cancers13020356
Cheng, P. et al. FOXD1-ALDH1A3 signaling is a determinant for the self-renewal and tumorigenicity of mesenchymal glioma stem cells. Cancer Res. 76, 7219–7230 (2016).
pubmed: 27569208
pmcid: 5161538
doi: 10.1158/0008-5472.CAN-15-2860
Li, J. et al. A specific inhibitor of ALDH1A3 regulates retinoic acid biosynthesis in glioma stem cells. Commun. Biol. 4, 1–16 (2021).
doi: 10.1038/s42003-021-02949-7
Clark, D. W. & Palle, K. Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets. Ann. Transl. Med. 4, 518 (2016).
pubmed: 28149880
pmcid: 5233526
doi: 10.21037/atm.2016.11.82
Januchowski, R., Wojtowicz, K. & Zabel, M. The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed. Pharmacother. 67, 669–680 (2013).
pubmed: 23721823
doi: 10.1016/j.biopha.2013.04.005
Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714–726 (2013).
pubmed: 24060863
doi: 10.1038/nrc3599
Januchowski, R. et al. Inhibition of ALDH1A1 activity decreases expression of drug transporters and reduces chemotherapy resistance in ovarian cancer cell lines. Int. J. Biochem. Cell Biol. 78, 248–259 (2016).
pubmed: 27443528
doi: 10.1016/j.biocel.2016.07.017
Quattrini, L. et al. Imidazo[1,2-a]pyridine derivatives as aldehyde dehydrogenase inhibitors: novel chemotypes to target glioblastoma stem cells. J. Med. Chem. 63, 4603–4616 (2020).
pubmed: 32223240
doi: 10.1021/acs.jmedchem.9b01910
Quattrini, L. et al. Progress in the field of aldehyde dehydrogenase inhibitors: novel Imidazo[1,2-a]pyridines against the 1A family. ACS Med. Chem. Lett. 11, 963–970 (2020).
pubmed: 32435412
pmcid: 7236222
doi: 10.1021/acsmedchemlett.9b00686
Shahcheraghi, S. H. et al. Therapeutic potential of curcumin in the treatment of glioblastoma multiforme. Curr. Pharm. Des. 25, 333–342 (2019).
pubmed: 30864499
doi: 10.2174/1381612825666190313123704
Purkayastha, S. et al. Curcumin blocks brain tumor formation. Brain Res. 1266, 130–138 (2009).
pubmed: 19368804
doi: 10.1016/j.brainres.2009.01.066
Gersey, Z. C. et al. Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species. BMC Cancer 17, 99 (2017).
pubmed: 28160777
pmcid: 5292151
doi: 10.1186/s12885-017-3058-2
Nelson, K. M. et al. The essential medicinal chemistry of curcumin: miniperspective. J. Med. Chem. 60, 1620–1637 (2017).
pubmed: 28074653
pmcid: 5346970
doi: 10.1021/acs.jmedchem.6b00975
Park, K.-S. et al. A curcumin-based molecular probe for near-infrared fluorescence imaging of tau fibrils in Alzheimer’s disease. Org. Biomol. Chem. 13, 11194–11199 (2015).
pubmed: 26488450
doi: 10.1039/C5OB01847A
Wang, X. et al. Curcumin exerts its tumor suppressive function via inhibition of NEDD4 oncoprotein in glioma cancer cells. Int. J. Oncol. 51, 467–477 (2017).
pubmed: 28627598
pmcid: 5505128
doi: 10.3892/ijo.2017.4037
Kamada, K. et al. Boron difluoride curcuminoid fluorophores with enhanced two-photon excited fluorescence emission and versatile living-cell imaging properties. Chem. Eur. J. 22, 5219–5232 (2016).
pubmed: 26919627
doi: 10.1002/chem.201504903
Hishii, M., Matsumoto, T. & Arai, H. Diagnosis and treatment of early-stage glioblastoma. Asian J. Neurosurg. 14, 589–592 (2019).
pubmed: 31143291
pmcid: 6516039
doi: 10.4103/ajns.AJNS_18_19
Caprioglio, D. et al. Triazole-curcuminoids: a new class of derivatives for ‘tuning’ curcumin bioactivities? Bioorg. Medicinal Chem. 24, 140–152 (2016).
doi: 10.1016/j.bmc.2015.11.044
Koeberle, A. et al. SAR studies on curcumin’s pro-inflammatory targets: discovery of prenylated pyrazolocurcuminoids as potent and selective novel inhibitors of 5-lipoxygenase. J. Med. Chem. 57, 5638–5648 (2014).
pubmed: 24920381
doi: 10.1021/jm500308c
Caldarelli, A., Penucchini, E., Caprioglio, D., Genazzani, A. A. & Minassi, A. Synthesis and tubulin-binding properties of non-symmetrical click C5-curcuminoids. Bioorg. Med. Chem. 21, 5510–5517 (2013).
pubmed: 23830698
doi: 10.1016/j.bmc.2013.05.053
Minassi, A., Sánchez-Duffhues, G., Collado, J. A., Muñoz, E. & Appendino, G. Dissecting the pharmacophore of curcumin. Which structural element is critical for which action? J. Nat. Prod. 76, 1105–1112 (2013).
pubmed: 23742639
doi: 10.1021/np400148e
Pabon, H. J. J. A synthesis of curcumin and related compounds. Recl. Trav. Chim. Pays-Bas 83, 379–386 (1964).
doi: 10.1002/recl.19640830407
Cai, L., Innis, R. B. & Pike, V. W. Radioligand development for PET imaging of beta-amyloid (Abeta)–current status. Curr. Med. Chem. 14, 19–52 (2007).
pubmed: 17266566
doi: 10.2174/092986707779313471
Agalave, S. G., Maujan, S. R. & Pore, V. S. Click chemistry: 1,2,3-triazoles as pharmacophores. Chem. Asian J. 6, 2696–2718 (2011).
pubmed: 21954075
doi: 10.1002/asia.201100432
Anand, P., Kunnumakkara, A. B., Newman, R. A. & Aggarwal, B. B. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4, 807–818 (2007).
pubmed: 17999464
doi: 10.1021/mp700113r
Van Nong, H. et al. Fabrication and vibration characterization of curcumin extracted from turmeric (Curcuma longa) rhizomes of the northern Vietnam. SpringerPlus 5, 1147 (2016).
pubmed: 27504245
pmcid: 4956636
doi: 10.1186/s40064-016-2812-2
Morgan, C. A., Parajuli, B., Buchman, C. D., Dria, K. & Hurley, T. D. N,N-diethylaminobenzaldehyde (DEAB) as a substrate and mechanism-based inhibitor for human ALDH isoenzymes. Chem. Biol. Interact. 234, 18–28 (2015).
pubmed: 25512087
doi: 10.1016/j.cbi.2014.12.008
Díez Valle, R., Hadjipanayis, C. G. & Stummer, W. Established and emerging uses of 5-ALA in the brain: an overview. J. Neurooncol. 141, 487–494 (2019).
pubmed: 30607705
doi: 10.1007/s11060-018-03087-7
Neira, J. A. et al. Aggressive resection at the infiltrative margins of glioblastoma facilitated by intraoperative fluorescein guidance. J. Neurosurg. 127, 111–122 (2017).
pubmed: 27715437
doi: 10.3171/2016.7.JNS16232
Katsevman, G. A., Turner, R. C., Urhie, O., Voelker, J. L. & Bhatia, S. Utility of sodium fluorescein for achieving resection targets in glioblastoma: increased gross- or near-total resections and prolonged survival. J. Neurosurg. 132, 914–920 (2019).
pubmed: 30738388
doi: 10.3171/2018.10.JNS181174
SigmaPlot Extract Graphs and Data Analysis (StatSys v12.3)SigmaPlot (RRID:SCR_003210). URL: http://www.sigmaplot.com/products/sigmaplot/ .
Xie, Y. et al. The human glioblastoma cell culture resource: validated cell models representing all molecular subtypes. EBioMedicine 2, 1351–1363 (2015).
pubmed: 26629530
pmcid: 4634360
doi: 10.1016/j.ebiom.2015.08.026
Azzalin, A. et al. A new pathway promotes adaptation of human glioblastoma cells to glucose starvation. Cells 9, 1249 (2020).
pmcid: 7290719
doi: 10.3390/cells9051249
Szatmari, T. et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci. 97, 546–553 (2006).
pubmed: 16734735
doi: 10.1111/j.1349-7006.2006.00208.x